Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24567546 | 0.80 | MEN1 (0.45) | TP53L3MBTL1ALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL1257511 | 0.79 | NPC1 (0.46) | RAB9ANPC1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL29951897 | 0.77 | ACACB (0.43) | TP53L3MBTL1ALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL9272660 | 0.77 | ALDH1A1 (0.48) | RAB9ANPC1TP53L3MBTL1ALDH1A1 | |
| SCHEMBL1517069 | 0.74 | ACACB (0.40) | TP53L3MBTL1ALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL1517071 | 0.74 | ACACB (0.40) | TP53L3MBTL1ALDH1A1SMN1; SMN2HSP90AA1 | |
| SCHEMBL3719041 | 0.73 | HCAR3 (0.53) | ACACBMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL20714561 | 0.71 | NPC1 (0.47) | RAB9ANPC1ACACBMEN1KMT2A | |
| SCHEMBL23507732 | 0.71 | NPC1 (0.47) | RAB9ANPC1ACACBMEN1KMT2A | |
| SCHEMBL2068114 | 0.70 | NPC1 (0.50) | RAB9ANPC1ALDH1A1TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2797884-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2794586-A1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623860-B2 | Azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8530460-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| WO-2013098375-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013098375-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| WO-2013092616-A1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092616-A1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172316-A1 | New azetidine derivatives, pharmaceutical compositions and uses thereof | QDPR, AZI2, CYP2C19 | RAB9A 256/4885NPC1 463/4885TP53 4251/4885 |
| US-20130158004-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | RAB9A 282/4885NPC1 39/4885TP53 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.